Immunohistochemical study of adhesion molecules in irritable bowel syndrome: A comparison to inflammatory bowel diseases

Mitselou, Antigony; Grammeniatis, Vasileios; Varouktsi, Anna; Papadatos, Stamatis S; Klaroudas, Antonios; Katsanos, Konstantinos; Galani, Vasiliki

Immunohistochemical study of adhesion molecules in irritable bowel syndrome: A comparison to inflammatory bowel diseases

Document Type : Original Article

Authors

¹ Department of Forensic Pathology, Histology-Embryology, Medical School, University of Ioannina, Ioannina, Greece

² Department of Paediatrics, General Hospital of Ioannina, Ioannina, Greece

³ Department of Internal Medicine, Ippokratio Hospital, Thessaloníki, Greece

⁴ 3rd Department of Internal Medicine, National and Kapodistrian University of Athens Medical School, Sotiria General Hospital, Athens, Greece

⁵ Department of Anatomy, Histology-Embryology, Medical School, University of Ioannina, Ioannina, Greece

⁶ 1st Department of Internal Medicine and Hepato-Gastroenterology Unit, Medical School, University of Ioannina, Ioannina, Greece

Abstract

Background: The surface of endothelial cells is covered with cell adhesion molecules including E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) that mediate the adhesion and extravasation of leukocytes and play a pivotal role in inflammatory response. The aim of this study was to investigate the role of expression of adhesion molecules in inflammatory bowel disease (IBD) patients, irritable bowel syndrome (IBS) patients, and normal colonic mucosa. Materials and Methods: IBS and IBD patients along with normal colonic mucosa were recruited in the study. In all groups, two biopsies were taken from each of the three anatomical sites (terminal ileum, cecum, and rectum). Three monoclonal antibodies, E-selectin mAb, VCAM-1 mAb, and ICAM-1 mAb, were applied for immunohistochemical analysis. Results: In IBD patients, the expression of intensity of E-selectin, VCAM-1, and ICAM-1 was found decreased, at least in cecum and rectum, in comparison with IBS patients and controls (P < 0.001, P < 0.005, and P < 0.007, respectively). Comparison of the expression of intensity of the aforementioned molecules in IBS patients and controls revealed significant augmentation at the cecum and rectum of IBS patients. Conclusions: The expression of adhesion molecules appeared lower in IBD patients compared to IBS patients and controls. In addition, the expression of adhesion molecules appeared higher in IBS compared to the control group. Therefore, it could be hypothesized that the expression of adhesion molecules could be considered as an early event in the process of proinflammatory IBS group and may be other factors play a crucial role in the process of intestinal inflammation in IBD patients.

Keywords

References

1.	Wahl SM, Feldman GM, McCarthy JB. Regulation of leukocyte adhesion and signaling in inflammation and disease. J Leukoc Biol 1996;59:789-96.
2.	Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1715-35.
3.	Tanaka S, Sakata Y, Morimoto K, Tambe Y, Watanabe Y, Honda G, et al. Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. Planta Med 2001;67:108-13.
4.	Vainer B. Role of cell adhesion molecules in inflammatory bowel diseases. Scand J Gastroenterol 1997;32:401-10.
5.	Thomas PD, Forbes A, Price AB, Nicholls RJ, Ciclitira PJ. Differential expression of cell adhesion molecules within inflamed ileal pouch mucosa: Relationship to recruited cell subtypes. Eur J Gastroenterol Hepatol 2002;14:137-44.
6.	Scaldaferri F, Correale C, Gasbarrini A, Danese S. Mucosal biomarkers in inflammatory bowel disease: Key pathogenic players or disease predictors? World J Gastroenterol 2010;16:2616-25.
7.	Arijs I, De Hertogh G, Machiels K, Van Steen K, Lemaire K, Schraenen A, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol 2011;106:748-61.
8.	Ohman L, Simrén M. Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-73.
9.	Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010;1:97-105.
10.	Sinagra E, Pompei G, Tomasello G, Cappello F, Morreale GC, Amvrosiadis G, et al. Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol 2016;22:2242-55.
11.	Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 2017;6:1-8.
12.	Kazimierczak P, Wisniewska-Jarasinka M, Drewosli J. Adhesion molecules in inflammatory bowel disease. Gastroenterol Pol 2000;7:269-75.
13.	Kintman D, Li X, Thorlaccus H. Important role of P-selectin for leucocyte recruitment, hepatocellular injury and apoptosis in endotoxemic mice. Clin Diagn Lab Immunol 2004;11:56-62.
14.	Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
15.	Lazaris AC, Dicoglou C, Tseleni-Balafouta S, Paraskevakou H, Davaris PS. In situ expression of E-selectin and intercellular adhesion molecule-1 in chronic inflammatory diseases of the gastrointestinal tract. APMIS 1999;107:819-27.
16.	Cellier C, Patey N, Fromont-Hankard G, Cervoni JP, Leborgne M, Chaussade S, et al. In-situ endothelial cell adhesion molecule expression in ulcerative colitis. E-selectin in-situ expression correlates with clinical, endoscopic and histological activity and outcome. Eur J Gastroenterol Hepatol 1997;9:1197-203.
17.	Vegter S, Tolley K, Wilson Waterworth T, Jones H, Jones S, Jewell D. Meta-analysis using individual patient data: Efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2013;38:284-93.
18.	Zarbock A, Ley K. Mechanisms and consequences of neutrophil interaction with the endothelium. Am J Pathol 2008;172:1-7.
19.	Gulubova MV, Manolova IM, Vlaykova TI, Prodanova M, Jovchev JP. Adhesion molecules in chronic ulcerative colitis. Int J Colorectal Dis 2007;22:581-9.
20.	Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992;103:840-7.
21.	Vainer B, Neles OH. Changed colonic profile of P-selectine, platelet-endothelial cell adhesion molecule-1 (PCAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel diseases. Clin Exp Imunol 2000;121:242-7.
22.	Shanahan F, Karp LC, Targan SR. Inflammatory BowelDisease: From Bench to Bedside. second edition.Targan SR, Shanahan F, Karp LC, editors. New York: Springer; 2005.
23.	Miner PB Jr., Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: A randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 2006;23:1403-13.
24.	van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr, A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006;23:1415-25.
25.	Sinagra E, Romano C, Cottone N. Phychopharmacological treatment and psychological intervention in irritable bowel syndrome. Gastroenterol Res Pract 2012;2012:486067.
26.	Lee YJ, Park KS. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J Gastroenterol 2014;20:2456-69.
27.	Keely S, Walker MM, Marks E, Talley NJ. Immune dysregulation in the functional gastrointestinal disorders. Eur J Clin Invest 2015;45:1350-9.
28.	Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20.
29.	Ng QX, Soh AYS, Loke W, Lim DY, Yeo WS. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res 2018;11:345-9.
30.	Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014;63:1737-45.
31.	Fiocchi C. Intestinal inflammation: A complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997;273:G769-75.
32.	Wittchen ES. Endothelial signaling in paracellular and transcellular leukocyte transmigration. Front Biosci (Landmark Ed) 2009;14:2522-45.
33.	Pooley N, Ghosh L, Sharon P. Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. Dig Dis Sci 1995;40:219-25.
34.	Petagna L, Antonelli A, Ganini C, Bellato V, Campanelli M, Divizia A, et al. Pathophysiology of Crohn's disease inflammation and recurrence. Biol Direct 2020;15:23.
35.	Zhang J, Wang C, Guo Z, Da B, Zhu W, Li Q. miR-223 improves intestinal inflammation through inhibiting the IL-6/STAT3 signaling pathway in dextran sodium sulfate-induced experimental colitis. Immun Inflamm Dis 2021;9:319-27.
36.	Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876-88.
37.	Galani V, Constantopoulos S, Manda-Stachouli C, Frangou-Lazaridis M, Mavridis A, Vassiliou M, et al. Additional proteins in BAL fluid of Metsovites environmentally exposed to asbestos: More evidence of “protection” against neoplasia? Chest 2002;121:273-8.
38.	Huang C, Dong J, Jin X, Ma H, Zhang D, Wang F, et al. Intestinal anti-inflammatory effects of fuzi-ganjiang herb pair against DSS-induced ulcerative colitis in mice. J Ethnopharmacol 2020;261:112951.
39.	Mitselou A, Grammeniatis V, Varouktsi A, Papadatos SS, Katsanos K, Galani V. Proinflammatory cytokines in irritable bowel syndrome: A comparison with inflammatory bowel disease. Intest Res 2020;18:115-20.
40.	Mitselou A, Galani V, Skoufi U, Arvanitis DL, Lampri E, Ioachim E. Syndecan-1, epithelial-mesenchymal transition markers (E-cadherin/β-catenin) and neoangiogenesis-related proteins (PCAM-1 and Endoglin) in colorectal cancer. Anticancer Res 2016;36:2271-80.

Advanced Biomedical Research